腱鞘巨细胞瘤（TGCT）的最佳临床管理：专家共识文件
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
作者信息
Stacchiotti Silvia, Dürr Hans Roland, Schaefer Inga-Marie, Woertler Klaus, Haas Rick, Trama Annalisa, Caraceni Augusto, Bajpai Jyoti, Baldi Giacomo Giulio, Bernthal Nicholas, Blay Jean-Yves, Boye Kjetil, Broto Javier-Martin, Chen Wei-Wu Tom, Dei Tos Paolo Angelo, Desai Jayesh, Emhofer Stephan, Eriksson Mikael, Gronchi Alessandro, Gelderblom Hans, Hardes Jendrik, Hartmann Wolfgang, Healey John, Italiano Antoine, Jones Robin L, Kawai Akira, Leithner Andreas, Loong Herbert, Mascard Eric, Morosi Carlo, Otten Nadine, Palmerini Emanuela, Patel Shreyaskumar R, Reichardt Peter, Rubin Brian, Rutkowski Piotr, Sangalli Claudia, Schuster Kathrin, Seddon Beatrice M, Shkodra Morena, Staals Eric L, Tap William, van de Rijn Matt, van Langevelde Kirsten, Vanhoenacker Filip M M, Wagner Andrew, Wiltink Lisette, Stern Sydney, Van de Sande Van Michiel, Bauer Sebastian
机构信息
Department of cancer medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Department of Orthopaedics and Trauma Surgery, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
出版信息
Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6.
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A global consensus meeting was organized in June 2022, involving experts from several disciplines and patient representatives from SPAGN to define the best evidence-based practice for the optimal approach to TGCT and generate the recommendations presented herein.
腱鞘巨细胞瘤（TGCT）是一种罕见的、具有局部侵袭性的间充质肿瘤，起源于关节、滑囊和腱鞘。TGCT包括结节型和弥漫型，前者大多病程进展缓慢，后者则具有局部侵袭性行为。虽然TGCT通常不会危及生命，但可能会引起慢性疼痛，并对功能和生活质量（QoL）产生不利影响。CSFR1抑制剂对症状和生活质量有益，但在大多数国家无法获得。在选择最合适的治疗方法时存在的不确定性程度，以及缺乏关于TGCT临床管理的指南，使得全球范围内新治疗方法的采用不一致，患者的治疗效果欠佳。2022年6月组织了一次全球共识会议，邀请了来自多个学科的专家和SPAGN的患者代表，以确定TGCT最佳治疗方法的最佳循证实践，并提出本建议。
Zotero 插件